Welcome to our dedicated page for Insight Molecular Diagnostics SEC filings (Ticker: IMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insight Molecular Diagnostics Inc.'s SEC filings document a molecular diagnostics issuer developing donor-derived cell-free DNA assays for transplant monitoring. Current reports and proxy materials cover operating results, GraftAssure product disclosures, regulatory and clinical-development updates, investor-presentation materials, and capital-structure matters tied to financing and equity compensation.
Its filings also describe governance subjects including shareholder voting provisions, bylaws, board and executive compensation matters, equity incentive plan awards, and material agreements for specimen collection services related to GraftAssureCore testing.
Insight Molecular Diagnostics Inc. reported continuing early-stage commercialization with very limited revenue and significant losses for the quarter ended June 30, 2026. Net revenue was $239,000 in the quarter and $271,000 for the first six months of 2026, down sharply from the prior-year period, driven by a business heavily concentrated in one life sciences customer and early GraftAssureIQ kitted product sales.
The company recorded a net loss of $11.3 million for the quarter and $15.6 million year-to-date, with operating expenses of $11.6 million in the quarter largely from research and development and commercialization activities. Operating cash outflow was $16.9 million in the first half. Liquidity was supported by a February 2026 registered direct offering that generated $24.6 million of net proceeds, including an investment from strategic partner Bio-Rad, raising cash and cash equivalents to $17.8 million plus $972,000 of restricted cash at June 30, 2026. Contingent consideration liabilities related to past acquisitions declined to $40.2 million after remeasurement, and total shareholders’ deficit narrowed from $31.5 million to $21.3 million. Management’s going-concern analysis concludes that, after planned cost controls and the recent financing, it expects to have sufficient cash for at least 12 months, though it still anticipates ongoing operating losses and negative cash flows as it develops transplant and oncology diagnostics.
Insight Molecular Diagnostics Inc. reported that it issued a press release on August 10, 2026 announcing financial results for the three and six months ended June 30, 2026; the release is furnished as Exhibit 99.1 and is not treated as filed under securities laws. The company also disclosed receiving an Additional Information Request (AIR) from the FDA regarding its submission for the GraftAssureDx test and must provide a complete response within 180 days. The company characterizes the AIR as a routine part of the FDA submission process, states it is prepared to respond, and anticipates one more FDA meeting before the fourth quarter of 2026. Forward‑looking statements cautions are included.
Insight Molecular Diagnostics Inc. director Lou Silverman reported a routine tax-related share disposition. On July 1, 2026, 7,700 shares of common stock valued at $5.69 per share were withheld by the company to cover tax obligations from the vesting of 35,000 restricted stock units granted on July 1, 2025. The footnote clarifies that Silverman did not sell any shares in the market, and he now directly holds 55,807 shares after this withholding.
Insight Molecular Diagnostics Inc. director Andrew J. Last reported a routine tax-withholding transaction related to equity compensation. On the vesting of 35,000 restricted stock units granted on July 1, 2025, the company withheld 7,700 shares of common stock at a value of $5.69 per share to cover tax obligations. This was not an open-market sale, and the reporting person did not sell any shares. After this withholding, Last directly holds 58,752 shares of common stock.
Insight Molecular Diagnostics Inc. director Arno Andrew reported the vesting of 55,000 restricted stock units, with part of the award used to pay taxes. The company withheld 12,100 shares of Common Stock at a value of $5.69 per share to satisfy tax withholding obligations, and the filing states that no shares were sold on the market. After this tax-withholding disposition, Andrew directly holds 156,785 shares of Common Stock and also has indirect holdings through entities JBA Investments LLC and MJA Investments LLC, where he serves as manager with voting and dispositive power.
Insight Molecular Diagnostics Inc. reported results of its 2026 annual shareholder meeting, where shareholders approved an amendment to the 2018 Equity Incentive Plan adding 1,750,000 shares, bringing total shares authorized for equity awards to 5,550,000.
All four director nominees were elected, the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026 was ratified, and shareholders approved, on a non-binding advisory basis, named executive officer compensation. The meeting had a quorum with 23,954,212 shares represented, equal to 74.19% of the company’s voting power as of the record date.
SILVERMAN LOU reported acquisition or exercise transactions in this Form 4 filing.
Insight Molecular Diagnostics Inc. director Lou Silverman reported an equity award of 26,943 shares of Common Stock on 2026-06-11. These shares are structured as Restricted Stock Units that vest on the date of the next annual meeting of shareholders, contingent on his continued service through that date.
Following this grant, Silverman directly holds a total of 63,507 shares of Common Stock. The award carries a stated price of $0.00 per share, indicating it is compensation rather than an open-market purchase.
Insight Molecular Diagnostics Inc. director Andrew J. Last reported an equity award on Common Stock. He received 26,943 Restricted Stock Units at a price of $0.00 per share, increasing his direct holdings to 66,452 shares.
The Restricted Stock Units will vest on the date of the next annual meeting of shareholders, provided he continues serving the company from the grant date through that vesting date. This filing reflects routine, compensation-related share acquisition rather than an open-market purchase or sale.
Arno Andrew reported acquisition or exercise transactions in this Form 4 filing.
Insight Molecular Diagnostics director Arno Andrew received an equity grant. He was awarded 32,331 shares of Common Stock at a price of $0.00 per share as a grant or award. These Restricted Stock Units vest at the next annual meeting of shareholders, subject to his continued service. Following the grant, he directly holds 168,885 shares and also has 7,804 shares held indirectly through investment LLCs where he has voting and disposition power.
Insight Molecular Diagnostics reported a sharply smaller business in early 2026 but an improved bottom line driven by non-cash items and new equity capital. For the quarter ended March 31, 2026, net revenue was just $32 thousand versus $2.1 million a year earlier, as all revenue came from laboratory services in the United States. Despite this, net loss narrowed to $4.3 million from $6.7 million, helped by a $5.9 million decrease in the fair value of Chronix-related contingent consideration.
Operating expenses fell to $4.4 million from $8.1 million, while net cash used in operating activities increased to $7.6 million. The company strengthened liquidity through a February 2026 registered direct offering that generated $26.0 million in gross proceeds and about $24.6 million in net proceeds, contributing to $28.2 million in cash and cash equivalents at quarter-end. Total assets were $40.4 million, with $51.1 million in liabilities and a shareholders’ deficit of $10.7 million. Management concluded that, despite ongoing expected losses and negative operating cash flows, existing resources are sufficient to meet projected needs for at least 12 months, so substantial doubt about continuing as a going concern has been alleviated for this period.